Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

BACKGROUND: In the SPARTAN study, compared with placebo, apalutamide added to ongoing androgen deprivation therapy significantly prolonged metastasis-free survival (MFS) and time to symptomatic progression in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). Overa...

Descripción completa

Detalles Bibliográficos
Autores principales: Small, E J, Saad, F, Chowdhury, S, Oudard, S, Hadaschik, B A, Graff, J N, Olmos, D, Mainwaring, P N, Lee, J Y, Uemura, H, De Porre, P, Smith, A A, Zhang, K, Lopez-Gitlitz, A, Smith, M R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927320/
https://www.ncbi.nlm.nih.gov/pubmed/31560066
http://dx.doi.org/10.1093/annonc/mdz397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927320/
https://www.ncbi.nlm.nih.gov/pubmed/31560066
http://dx.doi.org/10.1093/annonc/mdz397

Ejemplares similares